Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Radiol. Sep 28, 2014; 6(9): 643-656
Published online Sep 28, 2014. doi: 10.4329/wjr.v6.i9.643
Table 1 Normal values for specific eroded surface, erosion depthand wall thickness as reported in literature for healthy patients
SexParameterChange with ageMean age Values
FES/BS (%)210-302.15 (0.36)[43] 3.23 (2.6-4.02)[22]
30-603.43 (2.68-4.4)[22] 1.85 (0.82-4.21)[27] 1.78“[43]
60-90 (post-meno)4.59 (3.72-5.66)[22] 4.2 (1.7)[24] 7.11 (2.9-16.9)[56] 4.0 (2.0)[57] 1.66 (0.66)[43]
All ages6.2 (2.9)[21]
E.De (μm)210-3056.8 (50.2-63.4)[22]
30-6063.4 (57.5-69.3)[22] 33.7 (24.4-46.6)[27]
60-90 (post-meno)50.8 (46.9-54.7)[22] 27.21 (2.27)[24] 49.11 (38.3-61.7)[56] 49.4 (12.1)[32]
W.Th (μm)10-3062.0 (8)[29]
30-6049.0 (9.1)[48] 37.2 (3.8)[51] 38.1 (28.6-68.8)[53] 56.2 (7.1)[50] 50.4 (7.4)[29]
60-90 (post-meno)48.81 [37.8-62.2][56] 33.9 (4.7)[51] 32.2 (23.2-39.3)[53] 39.5 (2.0)[32] 32.1 (4.13)[57] 44.3 (4.9)[50] 40.2 (4.6)[29]
All ages31-43.9[13] 49.0 (2.5)[21]
M and FES/BS(%)210-3016.3 (11.6-18.1)[102] 16.6 (5.6)[23]
30-604.03 (1.42)[11]
All ages1.35 (0.39)[31] 1.94 (0.76-4.93)[103]
E.De (μm)230-6062.6[11]
All ages28.9 (23.4-39.3)[31] 34.2 (22.8-51.3)[103]
W.Th (μm)10-3044.2 (5.7)[102] 41.4 (5.7)[23]
30-6061.9 (6.8)[11]
60-9059.4[13]
All ages51.6 (35.8-74.4)[103]
MES/BS(%)210-303.32 (2.34-4.7)[22] 6.3 (0.6)[49] 2.84 (1.27)[43]
30-603.55 (2.55-4.95)[22] 3.7 (0.9)[24] 1.81 (0.72-4.56)[27] 6.62[51] 1.722[43]
60-903.99 (3.11-5.13)[22] 3.7 (0.6)[24] 6.4+[49] 1.91 (0.42)[43]
E.De (μm)210-3066.1 (57.1-75.1)[22]
30-6064.1 (48.0-60.2)[22] 33.0 (3.16)[24] 35.6 (23.2-54.7)[27]
60-9046.3 (44.3-48.3)[22] 28.94 (1.78)[24]
W.Th (μm)10-3062.0 (8.1)[29] 32.8 (2.6)[49]
30-6050.2 (8.7)[48] 53 (8.6)[50] 49.2 (4.6)[29] 35.02[49]
60-9048.5 (8.6)[50] 43.8 (2.8)[29] 32.82[49]
All ages40.6[13]
Table 2 Change of eroded surface, erosion depth and wall thickness in common bone diseases (postmenopausal osteoporosis, male idiopathic osteoporosis, glucocorticoid induced osteoporosis) as reported in literature
DiseaseParameterChange Values1 1Significantly lower than control 2Significantly higher than control
PmOPW.Th (μm)40.74a (31.6-54.3)1[56] 36.2 (6.4)1[21] 28.3 (20.1-34.8)1[53] 35.3 (2.0)1[32] 28.0 (4.44)1[57] 29.3 (1.4)[73] 31.2 (0.4)-32.1 (0.5)[64] 41.8 (4.25)-49.0 (8.93)[67]
ES/BS (%)b5.3a (1.7-18.1)[56] 6.0 (3.0)[21] 4.8 (2.7)[57] 1.67 (0.48)[73] 4.9 (2.9)[71] 1.89 (0.12)-3.41 (0.5)[64] 4.49 (1.6) - 6.55 (1.62)[65] 2.18 (1.24)[61] 2.42 (Q 1.31-2.93)[72] 4.7 (Q 3.3-5.7)-5.2 (Q 3.2-6.9)[67]
E.De (μm)b55a (37.3-82)[56] 48.5 (43.8-53.2)[8] 50.0 (13.4)[32] 22 (5)[71] 13.5 (0.43)-15.8 (0.91)[64]
EV/BV (%)0.46 (0.04)-1.21 (0.29)[64]
MIOPES/BS (%)9.7 (1.7)[55] 7.5 (1.3-17.7)[58]
E.De (μm)b44.7 (9.3)[58]
W.Th (μm)b35.3 (7.5)1[58]
GC induced OPEV/BV (%)0.44 (0.1)[60]
ES/BS (%)b2.3 (0.4)[60] 4.06 (2.45)[61]
E.De (μm)15.0 (1.3)[60]
W.Th (μm)30.6 (0.8)[60]
Table 3 Change of eroded surface, erosion depth and wall thickness with treatment for postmenopausal osteoporosis as reported in literature
Treatment for PmOPParameterChangeValues11Significantly lower then no treatment2Significantly higher then no treatment
Bisphosphonates (oral/IV ibandronate, alendronate, risendronate)EV/BV (%)b0.40 (0.1)-0.50 (0.1)[60]
ES/BS (%)b2.2 (0.4)-2.6 (0.5)[60]
5.3 (2.75)[67]
1.29 (90%CI: 1.04-1.95)-1.62 (90%CI: 1.32-1.88)[66]
E.De (μm)b13.4 (1.0)-16.2 (1.0)[60]
45.6 (9.45)[67]
W.Th (μm)b30.0 (1.0)-31.4 (1.0)[60]
41.6 (4.86)[67]
Strontium ranelateES/BS (%)b2.92 (1.48-3.89)[52]
Strontium ranelate 6 mES/BS (%)1.21 (0.21)1[74]
hPTH (1-34)ES/BS (%)0.78 (0.11)[74]
(teriparatide)10.1 (4.9)2-11.8 (7.1)2[71]
3.51 (Q 2.67-5.64)-4.0 (Q 2.8-6.0)[72]
W.Th (μm)b22 (5)-28 (7)[71]
PTH (1-84)ES/BS (%)b1.75 (0.35)[73]
W.Th (μm)b33.1 (1.4)[73]